

Thompson (MS) Waltz (Mast)
(Evans) Wilson (FL)
Trone (Beyer) (Evans)

Wilson (SC)
(Timmons)

Matsui
McBath
McCollum
McEachin
McGovern
McNerney
Meeks
Meijer
Meng
Mfume
Moore (WI)
Morelle
Moulton
Mrvan
Murphy (FL)
Nadler
Napolitano
Neal
Neguse
Newhouse
Newman
Norcross
O'Halleran
Oberholte
Ocasio-Cortez
Omar
Palazzo
Pallone
Pannetta
Pappas
Pascarell
Payne
Perlmutter

Peters
Phillips
Pingree
Porter
Pressley
Price (NC)
Quigley
Raskin
Reed
Rice (NY)
Ross
Roybal-Allard
Ruiz
Ruppersberger
Rush
Ryan
Sánchez
Sarbanes
Scanlon
Schakowsky
Schiff
Schneider
Schrader
Schriber
Scott (VA)
Scott, David
Sewell
Sherman
Sherrill
Sires
Slotkin
Smith (WA)
Soto

Spanberger
Speier
Stansbury
Stanton
Stevens
Strickland
Suzoi
Swalwell
Takano
Thompson (CA)
Thompson (MS)
Titus
Tlaib
Tonko
Torres (CA)
Torres (NY)
Trahan
Trone
Underwood
Upton
Vargas
Veasey
Velázquez
Wasserman
Schultz
Waters
Watson Coleman
Welch
Wexton
Wild
Williams (GA)
Wilson (FL)
Yarmuth

NOT VOTING—6

Budd
Bustos
Cheney
Gonzalez (OH)
Johnson (LA)
Kinzinger

□ 1148

So the amendment was agreed to.
The result of the vote was announced
as above recorded.

MEMBERS RECORDED PURSUANT TO HOUSE
RESOLUTION 8, 117TH CONGRESS

Armstrong	Garcia (IL)	McHenry
(Reschenthaler)	(Takano)	(Rouzer)
Baird (Walorski)	Garcia (TX)	Meng (Kuster)
Barragan	(Gomez)	Newman (Beyer)
(Correa)	Gimenez (Diaz- Balart)	Owens (Moore (UT))
Bass (Blunt)	Green (TN)	Panetta (Gomez)
Bilirakis	(Fleischmann)	Price (NC)
(Fleischmann)	Harder (CA)	(Connolly)
Bowman (Evans)	(Gomez)	Rice (SC)
Brooks	Jayapal (Gomez)	(Meijer)
(Fleischmann)	Johnson (TX)	Roybal-Allard
Brown (OH)	(Beyer)	(Wasserman Schultz)
(Beyer)	Joyce (OH)	Ryan (Kaptur)
Cawthorn (Gaetz)	(Garbarino)	Salazar (Steube)
Clarke (NY)	Kahele (Takano)	Sánchez (Gomez)
(Velázquez)	Katko	Scott, David
Cooper (Correa)	(Garbarino)	(Correa)
Comer	Kelly (IL) (Blunt)	Sessions (Babin)
(Fleischmann)	Rochester)	Sires (Pallone)
Crist	Kind (Beyer)	Speier (Scanlon)
(Wasserman Schultz)	Kirkpatrick	Steel (Oberholte)
Cuellar (Pappas)	(Pallone)	Stewart (Moore (UT))
Curtis (Moore (UT))	Krishnamoorthi (Beyer)	Strickland
Davis, Danny K.	LaMalfa	(Takano)
(Gomez)	(Palazzo)	Suzoi (Beyer)
DeGette (Blunt)	Lawson (FL)	Taylor (Carter (TX))
Rochester)	(Wasserman Schultz)	Thompson (MS)
Deutch (Rice (NY))	Long	(Evans)
Donalds	(Fleischmann)	Trone (Beyer)
(Cammack)	Luetkemeyer	Waltz (Mast)
Espallat	(Meuser)	Wilson (FL)
(Correa)	Mace (Timmons)	(Evans)
Ferguson	Manning (Beyer)	Wilson (SC)
(Kustoff)	McClain	(Timmons)
Frankel, Lois	(Fitzgerald)	
(Wasserman Schultz)	McEachin	
	(Wexton)	

MOMENT OF SILENCE IN REMEM- BRANCE OF OFFICER WILLIAM F. EVANS

The SPEAKER pro tempore (Mr. NEAL). The Chair asks all those present in the Chamber, as well as Members and staff throughout the Capitol, to please rise for a moment of silence in remembrance of Officer William F. Evans, son of Massachusetts, United States Capitol Police Officer, who was killed in the line of duty defending our Capitol on April 2, 2021.

AMENDMENT NO. 2 OFFERED BY MR. LAMB

The SPEAKER pro tempore. Pursuant to clause 8 of rule XX, the unfinished business is the question on amendment No. 2, printed in part B of House Report 117-285, on which further proceedings were postponed and on which the yeas and nays were ordered.

The Clerk will redesignate the amendment.

The Clerk redesignated the amendment.

The SPEAKER pro tempore. The question is on the amendment offered by the gentleman from Pennsylvania (Mr. LAMB).

This is a 5-minute vote.

The vote was taken by electronic device, and there were—yeas 234, nays 189, not voting 6, as follows:

[Roll No. 104]

YEAS—234

Adams	Crist	Huffman
Aguilar	Crow	Jackson Lee
Allred	Cuellar	Jacobs (CA)
Auchincloss	David (KS)	Jayapal
Axne	Davis, Danny K.	Jeffries
Barragan	Dean	Johnson (GA)
Bass	DeFazio	Johnson (OH)
Beatty	DeGette	Johnson (SD)
Bera	DeLauro	Johnson (TX)
Beyer	DelBene	Jones
Bishop (GA)	Delgado	Joyce (OH)
Blumenauer	Demings	Kahele
Blunt Rochester	DeSaulnier	Kaptur
Bonamici	Deutch	Katko
Bourdeaux	Dingell	Keating
Bowman	Doggett	Kelly (IL)
Boyle, Brendan	Doyle, Michael	Khanna
F.	F.	Kildee
Brown (MD)	Escobar	Kilmer
Brown (OH)	Eshoo	Kim (CA)
Brownley	Espallat	Kim (NJ)
Bush	Evans	Kind
Butterfield	Fitzpatrick	Kirkpatrick
Carbajal	Fletcher	Krishnamoorthi
Cárdenas	Foster	Kuster
Carson	Frankel, Lois	Lamb
Carter (LA)	Galleo	Langevin
Cartwright	Garamendi	Larsen (WA)
Case	Garcia (IL)	Larson (CT)
Casten	Garcia (TX)	Lawrence
Castor (FL)	Golden	Lawson (FL)
Castro (TX)	Gomez	Lee (CA)
Cherfilus-	Gonzalez,	Lee (NV)
McCormick	Vicente	Leger Fernandez
Chu	Gottheimer	Levin (CA)
Ciilline	Green, Al (TX)	Levin (MI)
Clark (MA)	Griffith	Lieu
Clarke (NY)	Grijalva	Lofgren
Cleaver	Grothman	Lowenthal
Clyburn	Harder (CA)	Luria
Cohen	Hayes	Lynch
Connolly	Higgins (NY)	Mace
Cooper	Himes	Malinowski
Correa	Hollingsworth	Maloney,
Costa	Horsford	Carolyn B.
Courtney	Houlihan	Maloney, Sean
Craig	Hoyer	Manning

Aderholt	Garbarino	Moore (AL)
Allen	Garcia (CA)	Moore (UT)
Amodei	Gibbs	Mullin
Armstrong	Gimenez	Murphy (NC)
Arrington	Gohmert	Nehls
Babin	Gonzales, Tony	Norman
Bacon	Good (VA)	Owens
Baird	Gooden (TX)	Palmer
Balderson	Gosar	Pence
Banks	Granger	Perry
Barr	Graves (LA)	Pfluger
Bentz	Graves (MO)	Pocan
Bergman	Green (TN)	Posey
Bice (OK)	Greene (GA)	Reschenthaler
Biggs	Guest	Rice (SC)
Bilirakis	Guthrie	Rodgers (WA)
Bishop (NC)	Harris	Rogers (AL)
Boebert	Harshbarger	Rogers (KY)
Bost	Hartzler	Rose
Brady	Hern	Rosendale
Brooks	Herrell	Rouzer
Buchanan	Herrera Beutler	Roy
Buck	Hice (GA)	Rutherford
Bucshon	Higgins (LA)	Salazar
Burchett	Hill	Scalise
Burgess	Hinson	Schweikert
Hudson	Huizenga	Scott, Austin
Issa	Issa	Sessions
Jackson	Jackson	Simpson
Jacobs (NY)	Jacobs (NY)	Smith (MO)
Jordan	Jordan	Smith (NE)
Joyce (PA)	Joyce (PA)	Smith (NJ)
Keller	Keller	Smucker
Kelly (MS)	Kelly (MS)	Spartz
Kelly (PA)	Kelly (PA)	Staubert
Kustoff	Kustoff	Steel
LaHood	LaHood	Stefanik
LaMalfa	LaMalfa	Stell
Lamborn	Lamborn	Steube
Latta	Latta	Stewart
LaTurner	LaTurner	Taylor
Lesko	Lesko	Tenney
Letlow	Letlow	Thompson (PA)
Long	Long	Tiffany
Loudermilk	Loudermilk	Timmons
Lucas	Lucas	Turner
Luetkemeyer	Luetkemeyer	Valadao
Malliotakis	Malliotakis	Van Drew
Mann	Mann	Van Dwyne
Massie	Massie	Wagner
Mast	Mast	Walberg
McCarthy	McCarthy	Walorski
McCaul	McCaul	Waltz
McClain	McClain	Weber (TX)
McClintock	McClintock	Webster (FL)
McHenry	McHenry	Wenstrup
McKinley	McKinley	Westerman
Meuser	Meuser	Williams (TX)
Miller (IL)	Miller (IL)	Wilson (SC)
Miller (WV)	Miller (WV)	Wittman
Miller-Meeks	Miller-Meeks	Womack
Moolenaar	Moolenaar	Zeldin
Mooney	Mooney	

NAYS—189

AMENDMENT NO. 3 OFFERED BY MR. RASKIN

The SPEAKER pro tempore (Ms. LEE of California). Pursuant to clause 8 of rule XX, the unfinished business is the question on amendment No. 3, printed in part B of House Report 117-285, on which further proceedings were postponed and on which the yeas and nays were ordered.

The Clerk will redesignate the amendment.

The Clerk redesignated the amendment.

The SPEAKER pro tempore. The question is on the amendment offered by the gentleman from Maryland (Mr. RASKIN).

The vote was taken by electronic device, and there were—yeas 209, nays 214, not voting 6, as follows:

[Roll No. 105]

YEAS—209

Adams	Boyle, Brendan	Cherfilus-
Aguilar	F.	McCormick
Allred	Brown (MD)	Chu
Auchincloss	Brown (OH)	Ciilline
Axne	Brownley	Clark (MA)
Barragan	Bush	Clarke (NY)
Bass	Butterfield	Cleaver
Beatty	Carbajal	Clyburn
Bera	Cárdenas	Cohen
Beyer	Carson	Connolly
Bishop (GA)	Carter (LA)	Cooper
Blumenauer	Cartwright	Correa
Blunt Rochester	Casten	Costa
Bonamici	Castor (FL)	Courtney
Bourdeaux	Castro (TX)	Craig
Bowman		Crist

Crow
Cuellar
Davids (KS)
Davis, Danny K.
Dean
DeFazio
DeGette
DeLauro
DelBene
Delgado
DeSaulnier
Deutch
Dingell
Doggett
Doyle, Michael F.
Escobar
Eshoo
Espallat
Evans
Fletcher
Foster
Frankel, Lois
Gaetz
Galleo
Garamendi
Garcia (IL)
Garcia (TX)
Golden
Gomez
Gonzalez, Vicente
Green, Al (TX)
Grijalva
Harder (CA)
Hayes
Higgins (NY)
Himes
Horsford
Houlahan
Hoyer
Huffman
Jackson Lee
Jacobs (CA)
Jayapal
Jeffries
Johnson (GA)
Johnson (TX)
Jones
Kahle
Kaptur
Keating
Kelly (IL)
Khanna
Kildee
Kilmer

Kim (NJ)
Kind
Kirkpatrick
Krishnamoorthi
Kuster
Lamb
Langevin
Larsen (WA)
Larson (CT)
Lawrence
Lawson (FL)
Lee (CA)
Leger Fernandez
Levin (CA)
Levin (MI)
Lieu
Lofgren
Lowenthal
Luria
Lynch
Mace
Maloney, Carolyn B.
Maloney, Sean
Manning
Matsui
McBath
McCollum
McEachin
McGovern
McNerney
Meeks
Meng
Mfume
Moore (WI)
Morelle
Moulton
Mrvan
Nadler
Napolitano
Neal
Neguse
Newman
Norcross
Ocasio-Cortez
Omar
Pallone
Pappas
Pascrell
Payne
Perlmutter
Peters
Phillips
Pingree
Pocan
Porter

Pressley
Price (NC)
Quigley
Raskin
Rice (NY)
Ross
Roybal-Allard
Ruiz
Ruppersberger
Rush
Ryan
Sánchez
Sarbanes
Scanlon
Schakowsky
Schiff
Schneider
Schrader
Scott (VA)
Scott, David
Sewell
Sherman
Sherrill
Sires
Smith (WA)
Soto
Speier
Stansbury
Stanton
Stevens
Strickland
Suozi
Swaikwell
Takano
Thompson (CA)
Thompson (MS)
Titus
Tlaib
Tonko
Torres (CA)
Torres (NY)
Trahan
Trone
Underwood
Vargas
Veasey
Velázquez
Wasserman
Schultz
Waters
Watson Coleman
Welch
Wild
Williams (GA)
Wilson (FL)
Yarmuth

NAYS—214

Aderholt
Allen
Amodei
Armstrong
Arrington
Babin
Bacon
Baird
Balderson
Banks
Barr
Bentz
Bergman
Bice (OK)
Biggs
Bilirakis
Bishop (NC)
Boebert
Bost
Brady
Brooks
Buchanan
Buck
Buchoon
Burchett
Burgess
Calvert
Cammack
Carey
Carl
Carter (GA)
Carter (TX)
Case
Cawthorn
Chabot
Cline
Cloud
Clyde
Cole
Comer
Crawford

Crenshaw
Curtis
Davidson
Davis, Rodney
Demings
DesJarlais
Diaz-Balart
Donalds
Duncan
Dunn
Ellzey
Emmer
Estes
Fallon
Feenstra
Ferguson
Fischbach
Fitzgerald
Fitzpatrick
Fleischmann
Foxy
Franklin, C.
Scott
Fulcher
Gallagher
Garbarino
Garcia (CA)
Gibbs
Gimenez
Gohmert
Gonzales, Tony
Good (VA)
Gooden (TX)
Gosar
Gottheimer
Granger
Graves (LA)
Graves (MO)
Green (TN)
Greene (GA)
Griffith

Grothman
Guest
Guthrie
Harris
Harshbarger
Hartzler
Hern
Herrell
Herrera Beutler
Hice (GA)
Higgins (LA)
Hill
Hinson
Hollingsworth
Hudson
Huizenga
Issa
Jackson
Jacobs (NY)
Johnson (OH)
Johnson (SD)
Jordan
Joyce (OH)
Joyce (PA)
Katko
Keller
Kelly (MS)
Kelly (PA)
Kim (CA)
Kustoff
LaHood
LaMalfa
Lamborn
Latta
LaTurner
Lee (NV)
Lesko
Letlow
Long
Loudermilk
Lucas

Luetkemeyer
Malinowski
Malliotakis
Mann
Massie
Mast
McCarthy
McCaul
McClain
McClintock
McHenry
McKinley
Meijer
Meuser
Miller (IL)
Miller (WV)
Miller-Meeks
Moolenaar
Mooney
Moore (AL)
Moore (UT)
Mullin
Murphy (FL)
Murphy (NC)
Nehls
Newhouse
Norman
O'Halleran
Obernolte
Owens
Palazzo

Palmer
Panetta
Pence
Perry
Pfluger
Posey
Reed
Reschenthaler
Rice (SC)
Rodgers (WA)
Rogers (AL)
Rogers (KY)
Rose
Rosendale
Rouzer
Roy
Rutherford
Salazar
Scalise
Schrier
Schweikert
Scott, Austin
Sessions
Simpson
Slotkin
Smith (MO)
Smith (NE)
Smith (NJ)
Smucker
Spanberger
Spartz

Stauber
Steel
Stefanik
Steil
Steube
Stewart
Taylor
Tenney
Thompson (PA)
Tiffany
Timmons
Turner
Upton
Valadao
Van Drew
Van Dune
Wagner
Walberg
Walorski
Waltz
Weber (TX)
Webster (FL)
Wenstrup
Westerman
Wexton
Williams (TX)
Wilson (SC)
Wittman
Womack
Zeldin

NOT VOTING—6

Budd
Bustos

Cheney
Gonzalez (OH)

Johnson (LA)
Kinzinger

□ 1200

So the amendment was rejected.
The result of the vote was announced
as above recorded.

MEMBERS RECORDED PURSUANT TO HOUSE
RESOLUTION 8, 117TH CONGRESS

Armstrong
(Reschenthaler)
Baird (Walorski)
Barragan
(Correa)
Bass (Blunt
Rochester)
Bilirakis
(Fleischmann)
Bowman (Evans)
Brooks
(Fleischmann)
Brown (OH)
(Beyer)
Cawthorn (Gaetz)
Clarke (NY)
(Velázquez)
Cooper (Correa)
Comer
(Fleischmann)
Crist
(Wasserman
Schultz)
Cuellar (Pappas)
Curtis (Moore
(UT))
Davis, Danny K.
(Gomez)
DeGette (Blunt
Rochester)
Deutch (Rice
(NY))
Donalds
(Cammack)
Espallat
(Correa)
Ferguson
(Kustoff)
Frankel, Lois
(Wasserman)

Schultz
(Garcia (IL)
(Takano)
Garcia (TX)
(Gomez)
Gimenez (Diaz-
Balart)
Green (TN)
(Fleischmann)
Harder (CA)
(Gomez)
Jayapal (Gomez)
Johnson (TX)
(Beyer)
Joyce (OH)
(Garbarino)
Kahle (Takano)
Katko
(Garbarino)
Kelly (IL) (Blunt
Rochester)
Kind (Beyer)
Kirkpatrick
(Pallone)
Krishnamoorthi
(Beyer)
LaMalfa
(Palazzo)
Lawson (FL)
(Wasserman
Schultz)
Long
(Fleischmann)
Luetkemeyer
(Meuser)
Mace (Timmons)
Manning (Beyer)
McClain
(Fitzgerald)
McEachin

(Wexton)
McHenry
(Rouzer)
Meng (Kuster)
Newman (Beyer)
Owens (Moore
(UT))
Panetta (Gomez)
Price (NC)
(Connolly)
Rice (SC)
(Meijer)
Roybal-Allard
(Wasserman
Schultz)
Ryan (Kaptur)
Salazar (Steube)
Sánchez (Gomez)
Scott, David
(Correa)
Sessions (Babin)
Sires (Pallone)
Speier (Scanlon)
Steel (Obernolte)
Stewart (Moore
(UT))
Strickland
(Takano)
Suozi (Beyer)
Taylor (Carter
(TX))
Thompson (MS)
(Evans)
Trone (Beyer)
Waltz (Mast)
Wilson (FL)
(Evans)
Wilson (SC)

The SPEAKER pro tempore. The previous question is ordered on the bill, as amended.

The question is on the engrossment and third reading of the bill.

The bill was ordered to be engrossed and read a third time, and was read the third time.

MOTION TO RECOMMIT

Mr. LATTA. Madam Speaker, I have a motion to recommit at the desk.

The SPEAKER pro tempore. The Clerk will report the motion to recommit.

The Clerk read as follows:

Mr. Latta moves to recommit the bill H.R. 3617 to the Committee on the Judiciary.

The material previously referred to by Mr. LATTA is as follows:

At the end of the Rules Committee Print, add the following (and make such conforming changes as may be necessary):

TITLE II—HALT ALL LETHAL
TRAFFICKING OF FENTANYL

SEC. 201. SHORT TITLE.

This title may be cited as the “Halt All Lethal Trafficking of Fentanyl Act” or the “HALT Fentanyl Act”.

SEC. 202. CLASS SCHEDULING OF FENTANYL-RELATED SUBSTANCES.

Section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended by adding at the end of schedule I the following:

“(e)(1) Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a fentanyl-related substance, or which contains the salts, isomers, and salts of isomers of a fentanyl-related substance whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

“(2) For purposes of paragraph (1), except as provided in paragraph (3), the term ‘fentanyl-related substance’ means any substance that is structurally related to fentanyl by 1 or more of the following modifications:

“(A) By replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle.

“(B) By substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino, or nitro groups.

“(C) By substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups.

“(D) By replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle.

“(E) By replacement of the N-propionyl group with another acyl group.

“(3) A substance that satisfies the definition of the term ‘fentanyl-related substance’ in paragraph (2) shall nonetheless not be treated as a fentanyl-related substance subject to this schedule if the substance—

“(A) is controlled by action of the Attorney General under section 201; or

“(B) is otherwise expressly listed in a schedule other than this schedule.

“(4)(A) The Attorney General may by order publish in the Federal Register a list of substances that satisfy the definition of the term ‘fentanyl-related substance’ in paragraph (2).

“(B) The absence of a substance from a list published under subparagraph (A) does not negate the control status of the substance under this schedule if the substance satisfies the definition of the term ‘fentanyl-related substance’ in paragraph (2).”.

SEC. 203. REGISTRATION REQUIREMENTS RELATED TO RESEARCH.

(a) ALTERNATIVE REGISTRATION PROCESS FOR SCHEDULE I RESEARCH.—Section 303 of the Controlled Substances Act (21 U.S.C. 823) is amended by adding at the end the following:

“(1) SPECIAL PROVISIONS FOR PRACTITIONERS CONDUCTING CERTAIN RESEARCH WITH SCHEDULE I CONTROLLED SUBSTANCES.—

“(1) IN GENERAL.—Notwithstanding subsection (f), a practitioner may conduct research described in paragraph (2) of this subsection with 1 or more schedule I substances in accordance with subparagraph (A) or (B) of paragraph (3) of this subsection.

“(2) RESEARCH SUBJECT TO EXPEDITED PROCEDURES.—Research described in this paragraph is research that—

“(A) is with respect to a drug that is the subject of an investigational use exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act; or

“(B) is—

“(i) conducted by the Department of Health and Human Services or the Department of Veterans Affairs; or

“(ii) funded partly or entirely by a grant, contract, cooperative agreement, or other transaction from the Department of Health and Human Services or the Department of Veterans Affairs.

“(3) EXPEDITED PROCEDURES.—

“(A) RESEARCHER WITH A CURRENT SCHEDULE I OR II RESEARCH REGISTRATION.—

“(i) IN GENERAL.—If a practitioner is registered to conduct research with a controlled substance in schedule I or II, the practitioner may conduct research under this subsection on and after the date that is 30 days after the date on which the practitioner sends a notice to the Attorney General containing the following information, with respect to each substance with which the practitioner will conduct the research:

“(I) The chemical name of the substance.

“(II) The quantity of the substance to be used in the research.

“(III) Demonstration that the research is in the category described in paragraph (2), which demonstration may be satisfied—

“(aa) in the case of a grant, contract, cooperative agreement, or other transaction, or intramural research project, by identifying the sponsoring agency and supplying the number of the grant, contract, cooperative agreement, other transaction, or project; or

“(bb) in the case of an application under section 505(i) of the Federal Food, Drug, and Cosmetic Act, by supplying the application number and the sponsor of record on the application.

“(IV) Demonstration that the researcher is authorized to conduct research with respect to the substance under the laws of the State in which the research will take place.

“(ii) VERIFICATION OF INFORMATION BY HHS OR VA.—Upon request from the Attorney General, the Secretary of Health and Human Services or the Secretary of Veterans Affairs, as appropriate, shall verify information submitted by an applicant under clause (i)(III).

“(B) RESEARCHER WITHOUT A CURRENT SCHEDULE I OR II RESEARCH REGISTRATION.—

“(i) IN GENERAL.—If a practitioner is not registered to conduct research with a controlled substance in schedule I or II, the practitioner may send a notice to the Attorney General containing the information listed in subparagraph (A)(i), with respect to each substance with which the practitioner will conduct the research.

“(ii) ATTORNEY GENERAL ACTION.—The Attorney General shall—

“(I) treat notice received under clause (i) as a sufficient application for a research registration; and

“(II) not later than 45 days of receiving such a notice that contains all information required under subparagraph (A)(i)—

“(aa) register the applicant; or

“(bb) serve an order to show cause upon the applicant in accordance with section 304(c).

“(4) ELECTRONIC SUBMISSIONS.—The Attorney General shall provide a means to permit

a practitioner to submit a notification under paragraph (3) electronically.

“(5) LIMITATION ON AMOUNTS.—A practitioner conducting research with a schedule I substance under this subsection may only possess the amounts of schedule I substance identified in—

“(A) the notification to the Attorney General under paragraph (3); or

“(B) a supplemental notification that the practitioner may send if the practitioner needs additional amounts for the research, which supplemental notification shall include—

“(i) the name of the practitioner;

“(ii) the additional quantity needed of the substance; and

“(iii) an attestation that the research to be conducted with the substance is consistent with the scope of the research that was the subject of the notification under paragraph (3).

“(6) IMPORTATION AND EXPORTATION REQUIREMENTS NOT AFFECTED.—Nothing in this subsection alters the requirements of part A of title III, regarding the importation and exportation of controlled substances.”

(b) SEPARATE REGISTRATIONS NOT REQUIRED FOR ADDITIONAL RESEARCHER IN SAME INSTITUTION.—Section 302(c) of the Controlled Substances Act (21 U.S.C. 822(c)) is amended by adding at the end the following:

“(4) An agent or employee of a research institution that is conducting research with a controlled substance if—

“(A) the agent or employee is acting within the scope of the professional practice of the agent or employee;

“(B) another agent or employee of the institution is registered to conduct research with a controlled substance in the same schedule;

“(C) the researcher who is so registered—

“(i) informs the Attorney General of the name, position title, and employing institution of the agent or employee who is not separately registered;

“(ii) authorizes that agent or employee to perform research under the registration of the registered researcher; and

“(iii) affirms that any act taken by that agent or employee involving a controlled substance shall be attributable to the registered researcher, as if the researcher had directly committed the act, for purposes of any proceeding under section 304(a) to suspend or revoke the registration of the registered researcher; and

“(D) the Attorney General does not, within 30 days of receiving the information, authorization, and affirmation described in subparagraph (C), refuse, for a reason listed in section 304(a), to allow the agent or employee to possess the substance without a separate registration.”

(c) SINGLE REGISTRATION FOR RELATED RESEARCH SITES.—Section 302(e) of the Controlled Substances Act (21 U.S.C. 822(e)) is amended by adding at the end the following:

“(3)(A) Notwithstanding paragraph (1), a person registered to conduct research with a controlled substance under section 303(f) may conduct the research under a single registration if—

“(i) the research occurs exclusively on sites all of which are—

“(I) within the same city or county; and

“(II) under the control of the same institution, organization, or agency; and

“(ii) before commencing the research, the researcher notifies the Attorney General of each site where—

“(I) the research will be conducted; or

“(II) the controlled substance will be stored or administered.

“(B) A site described in subparagraph (A) shall be included in a registration described in that subparagraph only if the researcher

has notified the Attorney General of the site—

“(i) in the application for the registration; or

“(ii) before the research is conducted, or before the controlled substance is stored or administered, at the site.

“(C) The Attorney General may, in consultation with the Secretary, issue regulations addressing, with respect to research sites described in subparagraph (A)—

“(i) the manner in which controlled substances may be delivered to the research sites;

“(ii) the storage and security of controlled substances at the research sites;

“(iii) the maintenance of records for the research sites; and

“(iv) any other matters necessary to ensure effective controls against diversion at the research sites.”

(d) NEW INSPECTION NOT REQUIRED IN CERTAIN SITUATIONS.—Section 302(f) of the Controlled Substances Act (21 U.S.C. 822(f)) is amended—

(1) by striking “(f) The” and inserting “(f)(1) The”; and

(2) by adding at the end the following:

“(2)(A) If a person is registered to conduct research with a controlled substance and applies for a registration, or for a modification of a registration, to conduct research with a second controlled substance that is in the same schedule as the first controlled substance, or is in a schedule with a higher numerical designation than the schedule of the first controlled substance, a new inspection by the Attorney General of the registered location is not required.

“(B) Nothing in subparagraph (A) shall prohibit the Attorney General from conducting an inspection that the Attorney General determines necessary to ensure that a registrant maintains effective controls against diversion.”

(e) CONTINUATION OF RESEARCH ON SUBSTANCES NEWLY ADDED TO SCHEDULE I.—Section 302 of the Controlled Substances Act (21 U.S.C. 822) is amended by adding at the end the following:

“(h) CONTINUATION OF RESEARCH ON SUBSTANCES NEWLY ADDED TO SCHEDULE I.—If a person is conducting research on a substance when the substance is added to schedule I, and the person is already registered to conduct research with a controlled substance in schedule I—

“(1) not later than 90 days after the scheduling of the newly scheduled substance, the person shall submit a completed application for registration or modification of existing registration, to conduct research on the substance, in accordance with regulations issued by the Attorney General for purposes of this paragraph;

“(2) the person may, notwithstanding subsections (a) and (b), continue to conduct the research on the substance until—

“(A) the person withdraws the application described in paragraph (1) of this subsection; or

“(B) the Attorney General serves on the person an order to show cause proposing the denial of the application under section 304(c);

“(3) if the Attorney General serves an order to show cause as described in paragraph (2)(B) and the person requests a hearing, the hearing shall be held on an expedited basis and not later than 45 days after the request is made, except that the hearing may be held at a later time if so requested by the person; and

“(4) if the person sends a copy of the application described in paragraph (1) to a manufacturer or distributor of the substance, receipt of the copy by the manufacturer or distributor shall constitute sufficient evidence that the person is authorized to receive the substance.”

(f) TREATMENT OF CERTAIN MANUFACTURING ACTIVITIES AS COINCIDENT TO RESEARCH.—Section 302 of the Controlled Substances Act (21 U.S.C. 822), as amended by subsection (e), is amended by adding at the end the following:

“(i) TREATMENT OF CERTAIN MANUFACTURING ACTIVITIES AS COINCIDENT TO RESEARCH.—

“(1) IN GENERAL.—Except as provided in paragraph (3), a person who is registered to perform research on a controlled substance may perform manufacturing activities with small quantities of that substance, including activities described in paragraph (2), without being required to obtain a manufacturing registration, if—

“(A) the activities are performed for the purpose of the research; and

“(B) the activities and the quantities of the substance involved in the activities are stated in—

“(i) a notification submitted to the Attorney General under section 303(1);

“(ii) a research protocol filed with an application for registration approval under section 303(f); or

“(iii) a notification to the Attorney General that includes—

“(I) the name of the registrant; and

“(II) an attestation that the research to be conducted with the small quantities of manufactured substance is consistent with the scope of the research that is the basis for the registration.

“(2) ACTIVITIES INCLUDED.—Activities permitted under paragraph (1) include—

“(A) processing the substance to create extracts, tinctures, oils, solutions, derivatives, or other forms of the substance consistent with—

“(i) the information provided as part of a notification submitted to the Attorney General under section 303(1); or

“(ii) a research protocol filed with an application for registration approval under section 303(f); and

“(B) dosage form development studies performed for the purpose of requesting an investigational new drug exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)).

“(3) EXCEPTION REGARDING MARIHUANA.—The authority under paragraph (1) to manufacture substances does not include the authority to grow marihuana.”.

(g) TRANSPARENCY REGARDING SPECIAL PROCEDURES.—Section 303 of the Controlled Substances Act (21 U.S.C. 823), as amended by subsection (a), is amended by adding at the end the following:

“(m) TRANSPARENCY REGARDING SPECIAL PROCEDURES.—

“(1) IN GENERAL.—If the Attorney General determines, with respect to a controlled substance, that an application by a practitioner to conduct research with the substance should be considered under a process, or subject to criteria, different from the process or criteria applicable to applications to conduct research with other controlled substances in the same schedule, the Attorney General shall make public, including by posting on the website of the Drug Enforcement Administration—

“(A) the identities of all substances for which such determinations have been made;

“(B) the process and criteria that shall be applied to applications to conduct research with those substances; and

“(C) how the process and criteria described in subparagraph (B) differ from the process and criteria applicable to applications to conduct research with other controlled substances in the same schedule.

“(2) TIMING OF POSTING.—The Attorney General shall make information described in paragraph (1) public upon making a deter-

mination described in that paragraph, regardless of whether a practitioner has submitted such an application at that time.”.

SEC. 204. RULEMAKING.

(a) INTERIM FINAL RULES.—The Attorney General—

(1) shall, not later than 1 year of the date of enactment of this title, issue rules to implement this title and the amendments made by this title; and

(2) may issue the rules under paragraph (1) as interim final rules.

(b) PROCEDURE FOR FINAL RULE.—

(1) EFFECTIVENESS OF INTERIM FINAL RULES.—A rule issued by the Attorney General as an interim final rule under subsection (a) shall become immediately effective as an interim final rule without requiring the Attorney General to demonstrate good cause therefor, notwithstanding subparagraph (B) of section 553(b) of title 5, United States Code.

(2) OPPORTUNITY FOR COMMENT AND HEARING.—An interim final rule issued under subsection (a) shall give interested persons the opportunity to comment and to request a hearing.

(3) FINAL RULE.—After the conclusion of such proceedings, the Attorney General shall issue a final rule to implement this title and the amendments made by this title in accordance with section 553 of title 5, United States Code.

The SPEAKER pro tempore. Pursuant to clause 2(b) of rule XIX, the previous question is ordered on the motion to recommit.

The question is on the motion to recommit.

The question was taken; and the Speaker pro tempore announced that the noes appeared to have it.

Mr. LATTA. Madam Speaker, on that I demand the yeas and nays.

The SPEAKER pro tempore. Pursuant to section 3(s) of House Resolution 8, the yeas and nays are ordered.

The vote was taken by electronic device, and there were—yeas 202, nays 220, not voting 7, as follows:

[Roll No. 106]

YEAS—202

Aderholt	Clyde	Gooden (TX)
Allen	Cole	Gosar
Amodei	Comer	Granger
Armstrong	Crawford	Graves (LA)
Arrington	Crenshaw	Graves (MO)
Babin	Curtis	Green (TN)
Bacon	Davidson	Greene (GA)
Baird	Davis, Rodney	Griffith
Balderson	DesJarlais	Grothman
Banks	Diaz-Balart	Guest
Barr	Donalds	Guthrie
Bentz	Duncan	Harris
Bergman	Dunn	Harshbarger
Bice (OK)	Ellzey	Hartzler
Biggs	Emmer	Hern
Bilirakis	Estes	Herrell
Bishop (NC)	Fallon	Herrera Beutler
Boebert	Feenstra	Hice (GA)
Bost	Ferguson	Higgins (LA)
Brady	Fischbach	Hill
Brooks	Fitzgerald	Hinson
Buchanan	Fitzpatrick	Hollingsworth
Buck	Fleischmann	Hudson
Bucshon	Foxx	Huizenga
Burchett	Franklin, C.	Issa
Burgess	Scott	Jackson
Calvert	Fulcher	Jacobs (NY)
Cammack	Gaetz	Johnson (OH)
Carey	Gallagher	Johnson (SD)
Carl	Garbarino	Jordan
Carter (GA)	Garcia (CA)	Joyce (OH)
Carter (TX)	Gibbs	Joyce (PA)
Cawthorn	Gimenez	Katko
Chabot	Gohmert	Keller
Cline	Gonzales, Tony	Kelly (MS)
Cloud	Good (VA)	Kelly (PA)

Kim (CA)	Mullin	Smith (NJ)
Kustoff	Murphy (NC)	Smucker
LaHood	Nehls	Spartz
LaMalfa	Newhouse	Staubert
Lamborn	Norman	Steel
Latta	Obernolte	Stefanik
LaTurner	Owens	Steil
Lesko	Palazzo	Steube
Letlow	Palmer	Stewart
Long	Pence	Taylor
Loudermilk	Perry	Tenney
Lucas	Pfluger	Thompson (PA)
Luetkemeyer	Posey	Tiffany
Mace	Reed	Timmons
Malliotakis	Reschenthaler	Turner
Mann	Rice (SC)	Upton
Mast	Rodgers (WA)	Valadao
McCarthy	Rogers (AL)	Van Drew
McCaul	Rogers (KY)	Van Dyne
McClain	Rose	Wagner
McClintock	Rosendale	Walberg
McHenry	Rouzer	Walorski
McKinley	Roy	Waltz
Meijer	Rutherford	Weber (TX)
Meuser	Salazar	Webster (FL)
Miller (IL)	Scalise	Wenstrup
Miller (WV)	Schweikert	Westerman
Miller-Meeks	Scott, Austin	Williams (TX)
Moolenaar	Sessions	Wilson (SC)
Mooney	Simpson	Wittman
Moore (AL)	Smith (MO)	Womack
Moore (UT)	Smith (NE)	

NAYS—220

Adams	Escobar	Manning
Aguilar	Eshoo	Massie
Allred	Espallat	Matsui
Auchincloss	Evans	McBath
Axne	Fletcher	McCollum
Barragan	Foster	McEachin
Bass	Frankel, Lois	McGovern
Beatty	Gallego	McNerney
Bera	Garamendi	Meeks
Beyer	Garcia (IL)	Meng
Bishop (GA)	Garcia (TX)	Mfume
Blumenauer	Golden	Moore (WI)
Blunt Rochester	Gomez	Morelle
Bonamici	Gonzalez,	Moulton
Bourdeaux	Vicente	Mrvan
Bowman	Gottheimer	Murphy (FL)
Boyle, Brendan	Green, Al (TX)	Nadler
F.	Grijalva	Napolitano
Brown (MD)	Harder (CA)	Neal
Brown (OH)	Hayes	Neguse
Brownley	Higgins (NY)	Newman
Bush	Himes	Norcross
Butterfield	Horsford	O'Halleran
Carbajal	Houlahan	Ocasio-Cortez
Cárdenas	Hoyer	Omar
Carson	Huffman	Pallone
Carter (LA)	Jackson Lee	Panetta
Cartwright	Jacobs (CA)	Pappas
Case	Jayapal	Pascrell
Casten	Jeffries	Payne
Castor (FL)	Johnson (GA)	Perlmutter
Castro (TX)	Johnson (TX)	Peters
Cherfilus-	Jones	Phillips
McCormick	Kahele	Pingree
Chu	Kaptur	Pocan
Ciulline	Keating	Porter
Clark (MA)	Kelly (IL)	Pressley
Clarke (NY)	Khanna	Price (NC)
Cleaver	Kildee	Quigley
Clyburn	Kilmer	Raskin
Cohen	Kim (NJ)	Rice (NY)
Connolly	Kind	Ross
Cooper	Kirkpatrick	Roybal-Allard
Correa	Krishnamoorthi	Ruiz
Costa	Kuster	Ruppersberger
Courtney	Lamb	Rush
Craig	Langevin	Ryan
Crist	Larsen (WA)	Sánchez
Crow	Larson (CT)	Sarbanes
Cuellar	Lawrence	Scanlon
Davids (KS)	Lawson (FL)	Schakowsky
Davis, Danny K.	Lee (CA)	Schiff
Dean	Lee (NV)	Schneider
DeFazio	Leger Fernandez	Schrader
DeGette	Levin (CA)	Schrier
DeLauro	Levin (MI)	Scott (VA)
DelBene	Lieu	Scott, David
Delgado	Lofgren	Sewell
Demings	Lowenthal	Sherman
DeSaulnier	Luria	Sherrill
Deutch	Lynch	Sires
Dingell	Malinowski	Slotkin
Doggett	Maloney,	Smith (WA)
Doyle, Michael	Carolyn B.	Soto
F.	Maloney, Sean	Spanberger

Speier
Stansbury
Stanton
Stevens
Strickland
Suozi
Swalwell
Takano
Thompson (CA)
Thompson (MS)
Titus

Tlaib
Tonko
Torres (CA)
Torres (NY)
Trahan
Trone
Underwood
Vargas
Veasey
Velázquez

Wasserman
Schultz
Waters
Watson Coleman
Welch
Wexton
Wild
Williams (GA)
Wilson (FL)
Yarmuth

Bush
Butterfield
Cárdenas
Carson
Carter (LA)
Cartwright
Case
Casten
Castor (FL)
Castro (TX)
Cheriflus-

Huffman
Jackson Lee
Jacobs (CA)
Jayapal
Jeffries
Johnson (GA)
Johnson (TX)
Jones
Kahele
Kaptur
Keating
Kelly (IL)
Khanna

Payne
Perlmutter
Peters
Phillips
Pingree
Pocan
Porter
Pressley
Price (NC)
Quigley
Raskin
Rice (NY)
Ross

Harris
Harshbarger
Hartzler
Hern
Herrell
Herrera Beutler
Hice (GA)
Higgins (LA)
Hill
Hinson
Hollingsworth
Hudson
Huizenga

Mann
Massie
McCarthy
McCaul
McClain
McHenry
McKinley
Meijer
Meuser
Miller (IL)
Miller (WV)
Miller-Meeks
Moolenaar

Salazar
Scalise
Schweikert
Scott, Austin
Sessions
Simpson
Smith (MO)
Smith (NE)
Smith (NJ)
Smucker
Spart
Stauber

NOT VOTING—7

Budd
Bustos
Cheney

Gonzalez (OH)
Johnson (LA)
Kinzinger

Zeldin

□ 1215

Mr. BROWN of Maryland changed his vote from “yea” to “nay.”

So the motion to recommit was rejected.

The result of the vote was announced as above recorded.

MEMBERS RECORDED PURSUANT TO HOUSE RESOLUTION 8, 117TH CONGRESS

Armstrong
(Reschenthaler)
Baird (Walorski)
Barragán
(Correa)
Bass (Blunt
Rochester)
Bilirakis
(Fleischmann)
Bowman (Evans)
Brooks
(Fleischmann)
Brown (OH)
(Beyer)
Cawthorn (Gaetz)
Clarke (NY)
(Velázquez)
Cooper (Correa)
Comer
(Fleischmann)
Crist
(Wasserman
Schultz)
Cuellar (Pappas)
Curtis (Moore
(UT))
Davis, Danny K.
(Gomez)
DeGette (Blunt
Rochester)
Deutch (Rice
(NY))
Donalds
(Cammack)
Espallat
(Meuser)
(Correa)
Ferguson
(Kustoff)
Frankel, Lois
(Wasserman
Schultz)

Garcia (IL)
(Takano)
Garcia (TX)
(Gomez)
Gimenez (Diaz-
Balart)
Green (TN)
(Fleischmann)
Harder (CA)
(Gomez)
Jayapal (Gomez)
Johnson (TX)
(Beyer)
Joyce (OH)
(Garbarino)
Kahele (Takano)
Katko
(Garbarino)
Kelly (IL) (Blunt
Rochester)
Kind (Beyer)
Kirkpatrick
(Pallone)
Krishnamoorthi
(Beyer)
LaMalfa
(Palazzo)
Lawson (FL)
(Wasserman
Schultz)
Long
(Fleischmann)
Luetkemeyer
(Meuser)
Mace (Timmons)
Manning (Beyer)
McClain
(Fitzgerald)
McEachin
(Wexton)

McHenry
(Rouzer)
Meng (Kuster)
Newman (Beyer)
Owens (Moore
(UT))
Panetta (Gomez)
Price (NC)
(Connolly)
Rice (SC)
(Meijer)
Roybal-Allard
(Wasserman
Schultz)
Ryan (Kaptur)
Salazar (Steube)
Sánchez (Gomez)
Scott, David
(Correa)
Sessions (Babin)
Sires (Pallone)
Speier (Scanlon)
Steel (Oberholte)
Stewart (Moore
(UT))
Strickland
(Takano)
Suozi (Beyer)
Taylor (Carter
(TX))
Thompson (MS)
(Evans)
Trone (Beyer)
Waltz (Mast)
Wilson (FL)
(Evans)
Wilson (SC)
(Timmons)

Chu
Cicilline
Clark (MA)
Clarke (NY)
Cleaver
Clyburn
Cohen
Connolly
Correa
Costa
Courtney
Craig
Crist
Crow
Davids (KS)
Davis, Danny K.
Dean
DeFazio
DeGette
DeLauro
DelBene
Delgado
Demings
DeSaulnier
Deutsch
Dingell
Doggett
Doyle, Michael
F.
Escobar
Eshoo
Espallat
Evans
Fletcher
Foster
Frankel, Lois
Gaetz
Gallego
Garamendi
Garcia (IL)
Garcia (TX)
Golden
Gomez
Gonzalez,
Vicente
Gottheimer
Green, Al (TX)
Grijalva
Harder (CA)
Hayes
Higgins (NY)
Himes
Horsford
Houlihan
Hoyer

McCormick
Kilmer
Kim (NJ)
Kind
Kirkpatrick
Krishnamoorthi
Kuster
Lamb
Langevin
Larsen (WA)
Larson (CT)
Lawrence
Lawson (FL)
Lee (CA)
Lee (NV)
Leger Fernandez
Levin (CA)
Levin (MI)
Lieu
Loftgren
Lowenthal
Luria
Lynch
Malinowski
Maloney,
Carolyn B.
Maloney, Sean
Manning
Mast
Matsui
McBath
McClintock
McCollum
McEachin
McGovern
McNerney
Meeks
Meng
Mfume
Moore (WI)
Morelle
Moulton
Mrvan
Murphy (FL)
Nadler
Napolitano
Neal
Neguse
Newman
Norcross
O'Halleran
Ocasio-Cortez
Omar
Pallone
Panetta
Pascrell

Roybal-Allard
Ruiz
Ruppersberger
Rush
Ryan
Sánchez
Sarbanes
Scanlon
Schakowsky
Schiff
Schneider
Schrader
Schrier
Scott (VA)
Scott, David
Sewell
Sherman
Sherrill
Sires
Slotkin
Smith (WA)
Soto
Spanberger
Speier
Stansbury
Stanton
Stevens
Strickland
Suozi
Swalwell
Takano
Thompson (CA)
Thompson (MS)
Titus
Tlaib
Tonko
Torres (CA)
Torres (NY)
Trahan
Trone
Underwood
Vargas
Veasey
Velázquez
Wasserman
Schultz
Waters
Watson Coleman
Welch
Wexton
Wild
Williams (GA)
Wilson (FL)
Yarmuth

Jackson
Jacobs (NY)
Johnson (OH)
Johnson (SD)
Jordan
Joyce (OH)
Joyce (PA)
Katko
Keller
Kelly (MS)
Kelly (PA)
Kim (CA)
Kinzinger
Kustoff
LaHood
LaMalfa
Lamborn
Latta
LaTurner
Lesko
Letlow
Long
Loudermilk
Lucas
Luetkemeyer
Mace
Malliotakis

Mooney
Moore (AL)
Moore (UT)
Mullin
Murphy (NC)
Nehls
Newhouse
Norman
Oberholte
Owens
Palazzo
Palmer
Pappas
Pence
Perry
Pfluger
Posey
Reed
Reschenthaler
Rice (SC)
Rodgers (WA)
Rogers (AL)
Rogers (KY)
Rose
Rosendale
Rouzer
Roy
Rutherford

NOT VOTING—5

Budd
Bustos

Cheney
Johnson (LA)

□ 1231

So the bill was passed.

The result of the vote was announced as above recorded.

A motion to reconsider was laid on the table.

PERSONAL EXPLANATION

Ms. CHENEY. Madam Speaker, I missed all votes on 4/1 due to illness. Had I been present, I would have voted “nay” on rollcall No. 103, “nay” on rollcall No. 104, “nay” on rollcall No. 105, “yea” on rollcall No. 106, and “nay” on rollcall No. 107.

PERSONAL EXPLANATION

Mr. BUDD. Madam Speaker, I was unable to attend votes in D.C. due to an important constituent event. Had I been present, I would have voted “nay” on rollcall No. 103, “nay” on rollcall No. 104, “nay” on rollcall No. 105, “yea” on rollcall No. 106, and “nay” on rollcall No. 107.

MEMBERS RECORDED PURSUANT TO HOUSE RESOLUTION 8, 117TH CONGRESS

Armstrong
(Reschenthaler)
Baird (Walorski)
Barragán
(Correa)
Bass (Blunt
Rochester)
Bilirakis
(Fleischmann)
Bowman (Evans)
Brooks
(Fleischmann)
Brown (OH)
(Beyer)
Cawthorn (Gaetz)
Clarke (NY)
(Velázquez)
Cooper (Correa)
Comer

(Fleischmann)
Crist
(Wasserman
Schultz)
Cuellar (Pappas)
Curtis (Moore
(UT))
Davis, Danny K.
(Gomez)
DeGette (Blunt
Rochester)
Deutch (Rice
(NY))
Donalds
(Cammack)
Espallat
(Correa)
Ferguson
(Kustoff)
Frankel, Lois
(Wasserman
Katko)

The SPEAKER pro tempore. The question is on the passage of the bill.

The question was taken; and the Speaker pro tempore announced that the ayes appeared to have it.

Mr. BENTZ. Madam Speaker, on that I demand the yeas and nays.

The SPEAKER pro tempore. Pursuant to section 3(s) of House Resolution 8, the yeas and nays are ordered.

This will be a 5-minute vote.

The vote was taken by electronic device, and there were—yeas 220, nays 204, not voting 5, as follows:

[Roll No. 107]

YEAS—220

Adams
Aguilar
Allred
Auchincloss
Axne
Barragán
Bass

Beatty
Bera
Beyer
Bishop (GA)
Blumenauer
Blunt Rochester
Bonamici

Bourdeaux
Bowman
Boyle, Brendan
F.
Brown (MD)
Brown (OH)
Brownley

Aderholt
Allen
Amodei
Armstrong
Arrington
Babin
Bacon
Baird
Balderson
Banks
Barr
Bentz
Bergman
Bice (OK)
Biggs
Bilirakis
Bishop (NC)
Boebert
Bost
Brady
Brooks
Buchanan
Buck
Bucshon
Burchett
Burgess
Calvert
Cammack

NAYS—204

Carey
Carl
Carter (GA)
Carter (TX)
Cawthorn
Chabot
Cline
Cloud
Clyde
Cole
Comer
Crawford
Crenshaw
Cuellar
Curtis
Davidson
Davis, Rodney
DesJarlais
Diaz-Balart
Donalds
Duncan
Dunn
Ellzey
Emmer
Estes
Fallon
Feenstra
Ferguson

Fischbach
Fitzgerald
Fitzpatrick
Fleischmann
Foxy
Franklin, C.
Scott
Fulcher
Gallagher
Garbarino
Garcia (CA)
Garcia
Gibbs
Gimenez
Gohmert
Gonzales, Tony
Gonzalez (OH)
Good (VA)
Gooden (TX)
Gosar
Granger
Graves (LA)
Graves (MO)
Green (TN)
Greene (GA)
Griffith
Grothman
Guest
Guthrie